Thus, CAPE is implicated as a potent natural product for the prevention of CAVD by inhibiting activation of the AKT/NF-κB pathway and NLRP3 inflammasome. This evidence concerns the gene NLRP3 and congenital bilateral aplasia of vas deferens from CFTR mutation.